GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Cyclically Adjusted Price-to-FCF

Illumina (Illumina) Cyclically Adjusted Price-to-FCF : 28.70 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Illumina Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Illumina's current share price is $122.28. Illumina's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $4.26. Illumina's Cyclically Adjusted Price-to-FCF for today is 28.70.

The historical rank and industry rank for Illumina's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ILMN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 22.25   Med: 98.46   Max: 212.26
Current: 28.45

During the past years, Illumina's highest Cyclically Adjusted Price-to-FCF was 212.26. The lowest was 22.25. And the median was 98.46.

ILMN's Cyclically Adjusted Price-to-FCF is ranked better than
58.73% of 63 companies
in the Medical Diagnostics & Research industry
Industry Median: 35 vs ILMN: 28.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Illumina's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $1.095. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $4.26 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Illumina Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Illumina's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted Price-to-FCF Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.85 94.06 90.62 47.92 32.72

Illumina Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.92 55.43 44.56 32.35 32.72

Competitive Comparison of Illumina's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted Price-to-FCF falls into.



Illumina Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Illumina's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=122.28/4.26
=28.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Illumina's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.095/129.4194*129.4194
=1.095

Current CPI (Dec. 2023) = 129.4194.

Illumina Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.116 99.695 0.151
201406 1.037 100.560 1.335
201409 0.750 100.428 0.967
201412 0.513 99.070 0.670
201503 0.203 99.621 0.264
201506 0.871 100.684 1.120
201509 1.012 100.392 1.305
201512 2.229 99.792 2.891
201603 0.311 100.470 0.401
201606 1.176 101.688 1.497
201609 0.730 101.861 0.928
201612 1.216 101.863 1.545
201703 0.578 102.862 0.727
201706 0.741 103.349 0.928
201709 1.020 104.136 1.268
201712 1.473 104.011 1.833
201803 1.115 105.290 1.371
201806 1.473 106.317 1.793
201809 1.530 106.507 1.859
201812 1.546 105.998 1.888
201903 0.953 107.251 1.150
201906 0.644 108.070 0.771
201909 1.473 108.329 1.760
201912 2.591 108.420 3.093
202003 1.628 108.902 1.935
202006 1.358 108.767 1.616
202009 0.709 109.815 0.836
202012 2.324 109.897 2.737
202103 1.633 111.754 1.891
202106 1.422 114.631 1.605
202109 -2.118 115.734 -2.368
202112 1.350 117.630 1.485
202203 0.698 121.301 0.745
202206 0.344 125.017 0.356
202209 -1.898 125.227 -1.962
202212 0.376 125.222 0.389
202303 -0.272 127.348 -0.276
202306 0.367 128.729 0.369
202309 0.595 129.860 0.593
202312 1.095 129.419 1.095

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Illumina  (NAS:ILMN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Illumina Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (Illumina) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Executives
Aimee L Hoyt officer: SVP, Chief People Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen director, officer: Chief Executive Officer 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi officer: SVP Product Development 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno director C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen officer: VP, Chief Accounting Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell officer: Sr VP & General Counsel 5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank officer: Chief Public Affairs Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo officer: SVP Chief Medical Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins officer: SVP, Chief Information Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels officer: Chief of Global Operations 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley officer: President & CEO 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121

Illumina (Illumina) Headlines

From GuruFocus

Q3 2023 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc Acquires Grail Inc Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024